Scope Fluidics S.A., a specialist life science entity listed on...
Read More
Scope Fluidics extends the functionality of the BacterOMIC system diagnostic panel and begins its validation study
Scope Fluidics S.A., a specialist life science entity listed on the NewConnect...
Read More
Scope Fluidics: BacterOMIC system for identifying antibiotic resistance has obtained the European CE IVD marking approval
The BacterOMIC system, developed by the Scope Fluidics Group, has...
Read More
BacterOMIC system on the run-up to the medical diagnostics market authorization
Bacteromic Sp. z o.o., a company being a part of...
Read More
Scope Fluidics successfully completes validation of the extended BacterOMIC diagnostic panel and intends to launch the next phase of the Early Access Programme
Scope Fluidics S.A., a specialist life science entity listed on the NewConnect market, which designs and develops innovative...
Read More
Scope Fluidics extends the functionality of the BacterOMIC system diagnostic panel and begins its validation study
Scope Fluidics S.A., a specialist life science entity listed on the NewConnect market which develops innovative technological solutions for the...
Read More
Scope Fluidics: BacterOMIC system for identifying antibiotic resistance has obtained the European CE IVD marking approval
The BacterOMIC system, developed by the Scope Fluidics Group, has received a European CE marking certificate for in...
Read More
BacterOMIC system on the run-up to the medical diagnostics market authorization
Bacteromic Sp. z o.o., a company being a part of Scope Fluidics S.A. Group, has completed the validation...
Read More
Scope Fluidics Group’s SPV enters into cooperation with Technicolor Precision BioDevices (Technicolor Poland)
Bacteromic sp. z o.o., a member of the Scope Fluidics group developing innovative medical diagnostic devices, has signed...
Read More
Scope Fluidics launches clinical trials of the BacterOMIC system in second external laboratory
Scope Fluidics – a biotechnological company listed on NewConnect, developer of innovative medical diagnostics projects – begins validation...
Read More
Another SPV of Scope Fluidics with positive recommendation regarding ISO 13485:2016 compliance certification
Bacteromic – a member of the Scope Fluidics S.A. Capital Group – has successfully passed the ISO certification...
Read More
Scope Fluidics has commenced the verification of the BacterOMIC system, which is one of the elements of the preregistration procedure
Bacteromic – a member of the Scope Fluidics S.A. Capital Group – has announced the commencement of the...
Read More
Scope Fluidics obtains another European patent protecting the BacterOMIC technology
Bacteromic – a member of the Scope Fluidics S.A. Capital Group – has received a conditional decision from...
Read More
Scope Fluidics launches a manufacturing line for the Bacteromic system
Scope Fluidics – a biotechnological company listed on NewConnect, owner of innovative medical diagnostics projects – has completed...
Read More
Bacteromic obtains the first European patent for the technology for rapid determination of antibiotic resistance of bacteria
Bacteromic – a member of the Scope Fluidics S.A. Capital Group – announced that it has received a conditional decision from the European Patent Office (EPO) to grant a patent...
Read More
Scope Fluidics launches the BacterOMIC system prevalidation process
Bacteromic – a member of the Scope Fluidics S.A. Capital Group – is working according to the assumed schedule and has announced
Read More
BacterOMIC project awarded again
Paweł Dębski, PhD, Eng. from Scope Fluidics was among the winners of the international training competition “V4 Innovators in Israel Training Program”.
Read More
Scope Fluidics ready for BacterOMIC system industrialisation
Bacteromic – a member of the Scope Fluidics S.A. Capital Group – announced the completion of another, fourth milestone of the BacterOMIC project,
Read More
Scope Fluidics successfully tested the BacterOMIC system at the Microbiology Department of the National Tuberculosis and Lung Diseases Research Institute
Bacteromic – a member of the Scope Fluidics S.A. Capital Group – has successfully completed the second series of external pre-validation tests of the BacterOMIC
Read More
Scope Fluidics obtains €1.93 million of Horizon 2020 funding for the BacterOMIC project
Bacteromic – a company which belongs to the Scope Fluidics S.A. Capital Group – has announced that it received a positive recommendation for funding under Phase 2
Read MoreTwo Scope Fluidics projects among the most ground-breaking diagnostic products in the American Association for Clinical Chemistry competition
PCR|ONE and BacterOMIC, two innovative medical diagnostic systems developed by Scope Fluidics, a biotechnology company listed on NewConnect
Read MoreScope Fluidics aspiring to be awarded a prestigious Horyzont 2020 grant
Bacteromic – a company owned by Scope Fluidics S.A. Capital Group – is applying for funding for the BacterOMIC project under Phase 2 of the European SME
Read MoreEuropean Patent Office issues a positive opinion for the patent application regarding BacterOMIC system
Bacteromic Sp. z o.o., a company that belongs to the Scope Fluidics S.A. Capital Group, received from the European Patent Office (EPO) a „European search report” and a written opinion
Read MoreScope Fluidics completes the validation of BacterOMIC system’s functionality
Bacteromic, a company that belongs to the Scope Fluidics S.A. Capital Group, has reached another milestone of the BacterOMIC project. The primary assumption of this stage of works was to...
Read MoreCompletion of the first tests of the BacterOMIC system in the National Medicines Institute
Bacteromic, a subsidiary of Scope Fluidics – a biotechnological company listed on the NewConnect stock exchange, concluded the first tests of functionality of a prototype of the BacterOMIC system
Read MoreScope Fluidics begins first tests of the BacterOMIC system
Scope Fluidics – a biotechnological company listed on the NewConnect stock exchange and an owner of innovative medical diagnostics projects – entered into cooperation with the National Medicines Institute (NIL).
Read MoreCompletion of a stage of works on the Bacteromic project
The Management Board of Scope Fluidics S.A. (the “Company”) would like to announce that the second stage of R&D works on the Bacteromic system has been completed, in line with...
Read MoreCompletion of the first stage of the Bacteromic project
Management Board of Scope Fluidics S.A. (the “Company”) would like to announce that the first stage of R&D works on the Bacteromic system has been completed, in line with the...
Read More